[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) >> Individual ID:PBN__Benef_494 

# __Increased influenza vaccination__

## Articles mentionning this Benefit

* [Coronavirus disease 2019: The harms of exaggerated information and non‐evidence‐based measures](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_101.md)

## Category to which it belongs

* [Expanded vaccination capabilities lead to improved healthcare capacity, equitable distribution, and enhanced response and technological capabilities.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_31.md)

## Description of actual returns pertaining to this benefit

* [Private investors investing in companies involved in vaccine production, distribution, or promotion can benefit from increased demand for influenza vaccines.](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_538.md)

## Name of the Benefit

Promoting influenza vaccination can reduce the burden on healthcare systems and prevent additional deaths from influenza, especially among vulnerable populations

## Risks which can benefit from this action

* [Vaccination uptake](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_508.md)

## Stakeholders benefitting from this Benefit

* [General public](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_29.md)

